0.33
6.83%
-0.0242
Telesis Bio Inc stock is currently priced at $0.33, with a 24-hour trading volume of 146.69K.
It has seen a -6.83% decreased in the last 24 hours and a -30.82% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.3454 pivot point. If it approaches the $0.3073 support level, significant changes may occur.
Previous Close:
$0.3542
Open:
$0.336
24h Volume:
146.69K
Market Cap:
$9.93M
Revenue:
$30.00M
Net Income/Loss:
$-38.17M
P/E Ratio:
-0.2444
EPS:
-1.35
Net Cash Flow:
$-35.49M
1W Performance:
+3.64%
1M Performance:
-30.82%
6M Performance:
-58.75%
1Y Performance:
-88.21%
Telesis Bio Inc Stock (TBIO) Company Profile
Name
Telesis Bio Inc
Sector
Industry
Phone
858 228 4115
Address
9535 Waples Street, Suite 100, San Diego
Telesis Bio Inc Stock (TBIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Mar-18-21 | Downgrade | Evercore ISI | Outperform → In-line |
Mar-18-21 | Downgrade | Truist | Buy → Hold |
Oct-05-20 | Initiated | Goldman | Buy |
Jul-07-20 | Reiterated | H.C. Wainwright | Buy |
Jul-06-20 | Initiated | William Blair | Outperform |
Jun-26-20 | Initiated | SunTrust | Buy |
Jul-22-19 | Initiated | Jefferies | Buy |
Jun-18-19 | Initiated | ROTH Capital | Buy |
Dec-24-18 | Initiated | H.C. Wainwright | Buy |
Jul-23-18 | Initiated | Citigroup | Buy |
Jul-23-18 | Initiated | Evercore ISI | Outperform |
Jul-23-18 | Initiated | Leerink Partners | Outperform |
View All
Telesis Bio Inc Stock (TBIO) Latest News
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
GlobeNewswire Inc.
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Benzinga
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
Zacks Investment Research
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Telesis Bio Inc Stock (TBIO) Financials Data
Telesis Bio Inc (TBIO) Revenue 2024
TBIO reported a revenue (TTM) of $30.00 million for the quarter ending September 30, 2023, a +42.56% rise year-over-year.
Telesis Bio Inc (TBIO) Net Income 2024
TBIO net income (TTM) was -$38.17 million for the quarter ending September 30, 2023, a +27.75% increase year-over-year.
Telesis Bio Inc (TBIO) Cash Flow 2024
TBIO recorded a free cash flow (TTM) of -$35.48 million for the quarter ending September 30, 2023, a +29.84% increase year-over-year.
Telesis Bio Inc (TBIO) Earnings per Share 2024
TBIO earnings per share (TTM) was -$1.30 for the quarter ending September 30, 2023, a +27.62% growth year-over-year.
About Telesis Bio Inc
Telesis Bio Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio Inc. was incorporated in 2011 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):